Stanford Medicine Engineers Immune Cells with Metabolite Sensors to Track and Eradicate Aggressive Solid Tumors

Stanford researchers engineer immune cells with metabolic sensors to track and infiltrate solid tumors, doubling complete response rates in animal studies.

By: AXL Media

Published: Mar 25, 2026, 6:20 AM EDT

Source: Information for this report was sourced from Stanford Medicine

Harnessing Cancer Metabolism for Immune Navigation

A significant barrier in the field of immunotherapy has been the inability of engineered cells to effectively locate and penetrate solid tumors. While existing treatments like CAR-T cell therapy have seen success in blood cancers, they often fail against solid masses due to the difficulty of cell migration into dense tissue. Researchers at Stanford Medicine have proposed a solution by transforming immune cells into "bloodhounds" that track the abnormal metabolic signatures of malignancy. By sensing the small molecules that diffuse into the extracellular spaces around a tumor, these re-engineered cells can follow a chemical trail directly to the source of the disease.

Beyond the Limitations of Surface Protein Recognition

Conventional CAR-T therapies rely on receptors that must physically bind to proteins tethered to the surface of a cancer cell. This approach is often hampered by "T cell exhaustion," where cells become inactive before they can eliminate a solid tumor, and the challenge of finding proteins that are exclusive to cancer. The Stanford team, led by Assistant Professor Livnat Jerby, focused instead on the spatial issue of infiltration. Their research shifted the focus toward chemoattracting metabolites, such as phospholipids and cholesterol derivatives, which are produced in high concentrations by the rapid and uncontrolled proliferation of cancer cells.

Identifying Tumor Homing G-Protein Receptors

To identify the most effective genetic triggers for migration, the researchers utilized CRISPR technology to screen 256 candidate genes in natural killer (NK) cells. The results revealed a specific class of proteins known as G-protein coupled receptors, or thGPRs, which were consistently superior at driving immune cells into the heart of breast and ovarian tumors. Unlike traditional chemokine receptors, these thGPRs are specifically tuned to recognize the unique metabolic byproducts of a tumor’s dash to multiply. This discovery suggests that the very features that make a tumor aggressive and drug-resistant can be exploited as a "smoking gun" to guide the immune system.